Table 1.
The clinicopathological characteristics of LUAD in patients with TCGA.
| Characteristics | N% or median (range) |
|---|---|
| Age | |
| >65 | 262 (51.07%) |
| ≤65 | 241 (46.98%) |
| Data missing | 10 (1.95%) |
| Gender (%) | |
| Female | 276 (53.80%) |
| Male | 237 (46.20%) |
| path T-stage (%) | |
| T1 | 168 (32.75%) |
| T2 | 276 (53.80%) |
| T3 | 47 (9.16%) |
| T4 | 19 (3.70%) |
| Data missing | 3 (0.59%) |
| path N-stage (%) | |
| N0 | 330 (64.33%) |
| N1 | 95 (18.52%) |
| N2 | 74 (14.42%) |
| N3 | 2 (0.39%) |
| Data missing | 12 (2.34%) |
| path M-stage (%) | |
| M0 | 344 (67.06%) |
| M1 | 25 (4.87%) |
| Data missing | 144 (28.07%) |
| Pathologic stage (%) | |
| Stage I | 274 (53.41%) |
| Stage II | 121 (23.59%) |
| Stage III | 84 (16.37%) |
| Stage IV | 10 (1.95%) |
| Data missing | 24 (4.68%) |
| Primary therapy outcome (%) | |
| CR | 315 (61.40%) |
| PD | 68 (13.26%) |
| PR | 6 (1.17%) |
| SD | 37 (7.21%) |
| Data missing | 87 (16.96%) |
| TP53 status (%) | |
| Mut | 241 (46.98%) |
| WT | 267 (52.05%) |
| Data missing | 5 (0.97%) |